Imugene (AU:IMU)
ASX:IMU
Want to see AU:IMU full AI Analyst Report?
Top Page
Imugene
(Sydney:IMU)
Select Model
Select Model
Rating:40Underperform
Price Target:
AU$0.12
▼(-63.94% Downside)
Action:DowngradedDate:04/25/26
The score is weighed down primarily by weak financial performance (declining revenue, sustained losses, and weak operating cash flow). Technicals also remain negative with the price below all key moving averages and a negative MACD, with only near-oversold momentum offering limited offset. Valuation provides little support given negative earnings and no dividend yield data.
Positive Factors
Diversified clinical-stage pipeline
Having multiple clinical and preclinical candidates spreads scientific and regulatory risk across programs, increasing the chance that at least one asset advances. This diversity also enhances partnering and licensing optionality, supporting longer-term value creation independent of any single trial result.
Negative Factors
Sharp revenue decline
A very large revenue decline signals the absence of recurring commercial sales and a reliance on financing or one-off items. Over months this undermines sustainable funding sources, increases execution risk for trials, and reduces options to self-fund development without dilutive raises or deals.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified clinical-stage pipeline
Having multiple clinical and preclinical candidates spreads scientific and regulatory risk across programs, increasing the chance that at least one asset advances. This diversity also enhances partnering and licensing optionality, supporting longer-term value creation independent of any single trial result.
Read all positive factors
Imugene (IMU) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$50.23M
Dividend YieldN/A
Average Volume (3M)877.83K
Price to Earnings (P/E)―
Beta (1Y)1.88
Revenue GrowthN/A
EPS Growth55.94%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.13
Shares Outstanding372,105,470
10 Day Avg. Volume850,615
30 Day Avg. Volume877,834
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.15
Price to Sales (P/S)21.99
P/FCF Ratio-1.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.18
Revenue Forecast (FY)AU$5.00M
Imugene Business Overview & Revenue Model
Company Description
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccin...
How the Company Makes Money
Imugene is a clinical-stage biotechnology company and, based on publicly available high-level disclosures, it does not have a mature, recurring product-revenue business like a commercial-stage pharmaceutical company; specific current product sales...
Imugene Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.14M | 4.40M | 4.97M | 11.78M | 12.97M | 7.23M |
| Gross Profit | 2.79M | 4.40M | 4.97M | 9.57M | 10.56M | 5.27M |
| EBITDA | -58.98M | -67.42M | -147.98M | -47.42M | -48.06M | -23.72M |
| Net Income | -58.50M | -69.02M | -149.68M | -37.91M | -37.87M | -18.45M |
Balance Sheet | ||||||
| Total Assets | 67.67M | 83.59M | 151.40M | 197.06M | 147.61M | 71.81M |
| Cash, Cash Equivalents and Short-Term Investments | 14.14M | 21.94M | 94.54M | 153.15M | 99.89M | 29.49M |
| Total Debt | 5.02M | 10.65M | 2.19M | 553.47K | 673.43K | 271.03K |
| Total Liabilities | 25.80M | 38.56M | 33.14M | 7.44M | 8.90M | 6.79M |
| Stockholders Equity | 41.87M | 45.03M | 118.25M | 189.63M | 138.70M | 65.02M |
Cash Flow | ||||||
| Free Cash Flow | -59.70M | -90.03M | -108.80M | -29.78M | -30.93M | -18.58M |
| Operating Cash Flow | -62.92M | -75.57M | -101.73M | -29.78M | -30.67M | -13.13M |
| Investing Cash Flow | 2.86M | -12.70M | -7.25M | 9.63K | -414.16K | -5.48M |
| Financing Cash Flow | 40.66M | 17.37M | 49.43M | 82.98M | 101.35M | 17.99M |
Imugene Technical Analysis
Neutral
0.33
Price Trends
0.20
Negative
0.26
Negative
0.29
Negative
Market Momentum
-0.01
Negative
40.36
Neutral
80.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IMU, the sentiment is Neutral. The current price of 0.33 is above the 20-day moving average (MA) of 0.14, above the 50-day MA of 0.20, and above the 200-day MA of 0.29, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 40.36 is Neutral, neither overbought nor oversold. The STOCH value of 80.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:IMU.
Imugene Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | AU$4.89B | -342.48 | -2.08% | ― | 60.23% | -66.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$21.20M | -3.69 | 2509.60% | ― | ― | -36.89% | |
44 Neutral | AU$1.10B | -5.54 | -59.59% | ― | ― | -29.93% | |
42 Neutral | AU$109.06M | -3.40 | -69.20% | ― | ― | -19.21% | |
42 Neutral | AU$57.83M | -5.28 | -62.49% | ― | ― | 10.78% | |
40 Underperform | AU$50.23M | -0.70 | -134.65% | ― | ― | 55.94% |
* Healthcare Sector Average
AU:IMU
Imugene
0.13
-0.76
-85.86%
AU:IMM
Immutep Ltd
0.07
-0.18
-72.00%
AU:PTX
Prescient Therapeutics Limited
0.05
<0.01
10.20%
AU:TLX
Telix Pharmaceuticals
14.90
-11.78
-44.15%
AU:NOX
Noxopharm Ltd.
0.08
>-0.01
-1.30%
AU:CU6
Clarity Pharmaceuticals Ltd.
2.94
0.84
40.00%
Imugene Corporate Events
Imugene Seeks ASX Quotation for 15 Million New Shares
Apr 24, 2026
Imugene Limited has applied to the ASX for quotation of 15,077,309 new ordinary fully paid shares, with an issue date of April 24, 2026. The securities form part of a previously announced transaction, indicating an expansion of the company’s...
Imugene Secures $16m Funding as Shareholders Back Capital Raising
Apr 23, 2026
Imugene Limited has secured strong shareholder backing at its Extraordinary General Meeting, with all resolutions passed by poll, clearing the way for completion of its latest capital-raising initiatives. The approvals cover tranche two of an inst...
Imugene CEO Leslie Chong Increases Direct Shareholding via On-Market Purchase
Apr 22, 2026
Imugene chief executive Leslie Chong has increased her direct holding in the company, acquiring 65,053 ordinary fully paid shares on market at A$0.145 per share. Following the transaction, her direct stake has risen to 2,683,835 shares, while her ...
Imugene Cuts Potential Dilution as Expired Options and Rights Lapse
Apr 10, 2026
Imugene Limited has notified the market of the cessation of several classes of equity-linked securities, including more than 5.8 million options expiring on 31 March 2026 that lapsed unexercised. Additional options and restricted stock units, tota...
Imugene applies for ASX quotation of additional ordinary shares
Apr 8, 2026
Imugene Limited has applied to the ASX for quotation of 17,829 new ordinary fully paid shares, to be issued on 11 January 2026 following the conversion or exercise of existing options or other convertible securities. The modest increase in quoted ...
Imugene Issues Additional Unquoted Options as Part of Ongoing Capital Management
Apr 2, 2026
Imugene Limited has notified the market of the issue of a small tranche of unquoted options, with 4,544 IMUAJ options expiring on 30 June 2028 and exercisable at $0.86 being issued on 26 and 30 March 2026. These options form part of previously ann...
Imugene Seeks ASX Quotation for Shares Issued on Option Conversions
Apr 1, 2026
Imugene Limited has applied to the ASX for quotation of new fully paid ordinary shares that have been issued following the exercise of options or conversion of other convertible securities. The newly issued securities, dated 26 March 2026 and 30 M...
Imugene’s Lead CAR T Therapy Azer-cel Wins Prestigious ASCO 2026 Oral Slot
Apr 1, 2026
Imugene announced that new data from its lead CAR T program, azer-cel, has been selected for an oral presentation at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, the world’s premier oncology conference. The compe...
Imugene calls hybrid Extraordinary General Meeting with expanded online access
Mar 22, 2026
Imugene Limited has called an Extraordinary General Meeting to be held on 23 April 2026 at 9:00 a.m. Sydney time, offering both a physical venue in Sydney and a virtual option via the Automic online platform. The company is encouraging shareholder...
Imugene Issues 35.4 Million New Shares in ASX Placement
Mar 19, 2026
Imugene Limited has issued 35,445,999 fully paid ordinary shares at $0.18 per share under a previously announced placement, expanding its share capital on the ASX. The company confirmed the shares were issued without a prospectus under applicable ...
Imugene Seeks ASX Quotation for 35.4 Million New Shares
Mar 19, 2026
Imugene Limited has applied for quotation on the ASX of 35,445,999 new fully paid ordinary shares, with an issue date of 20 March 2026. The additional securities, issued as part of previously announced transactions, will expand the company’s...
Imugene Issues Additional Unquoted Options Under Existing Equity Arrangements
Mar 19, 2026
Imugene Limited has notified the market of the issue of new unquoted options under its existing equity arrangements. The company is issuing a total of 40,906 options, each expiring on 30 June 2028 with an exercise price of $0.86, across three sepa...
Imugene Seeks ASX Quotation for Additional Ordinary Shares
Mar 19, 2026
Imugene Limited has applied to the Australian Securities Exchange for quotation of 40,906 new fully paid ordinary shares. The new securities, issued on 19 March 2026 following the exercise or conversion of existing instruments, modestly expand the...
Imugene Clarifies Scale-Back Terms on Securities Purchase Plan
Mar 19, 2026
Imugene Limited has updated its Appendix 3B filing for a proposed issue of securities under a securities purchase plan, clarifying that any investor subscriptions may be scaled back at the company’s discretion. The clarification confirms tha...
Imugene Confirms EGM Date and Updates Securities Purchase Plan Timetable
Mar 18, 2026
Imugene Limited has updated its proposed securities issue announcement, confirming the date for an Extraordinary General Meeting and revising the timetable for its securities purchase plan. The update signals that the company is progressing with i...
Imugene launches structured capital raise with placement, SPP and warrants
Mar 17, 2026
Imugene Limited has launched a multi-instrument capital raising package comprising a two-tranche share placement of up to 66.7 million new shares at $0.18, a share purchase plan targeting about $8 million, and associated attaching and piggyback op...
Imugene Issues Additional Unquoted Options Under Capital Management Plan
Mar 12, 2026
Imugene Limited has notified the market of the issue of additional unquoted options under ASX code IMUAJ, each exercisable at $0.86 and expiring on 30 June 2028. A total of 2,872 options were issued across two tranches on 4 and 5 March 2026, as pa...
Imugene Seeks ASX Quotation for Additional Ordinary Shares
Mar 12, 2026
Imugene Limited has applied to the ASX for quotation of a small number of additional ordinary fully paid shares, following the exercise or conversion of existing options or other convertible securities. The new securities, totaling 2,872 IMU share...
Imugene outlines non-underwritten capital raising with strict offer restrictions
Mar 11, 2026
Imugene Limited has released a capital raising presentation outlining plans for a two-tranche, non-underwritten placement and a share purchase plan of new fully paid ordinary shares with attaching options. The offer is being conducted with the sup...
Imugene Launches Securities Purchase Plan Offering Shares and New Quoted Options
Mar 11, 2026
Imugene Limited has announced a new securities purchase plan, offering up to 44,444,444 ordinary fully paid shares alongside equal numbers of quoted options expiring in April 2027 and April 2029 at specified exercise prices. The offer, with a reco...
Imugene plans major equity and options issue to support growth
Mar 11, 2026
Imugene Limited has outlined plans for a new capital raising via a placement or similar issue of securities, detailing the proposed issuance of 66,666,667 ordinary fully paid shares. The company will also issue two tranches of quoted options, each...
Imugene Secures $12m Placement in $20m Capital Raise to Fund Azer-cel Trial
Mar 11, 2026
Imugene has launched a capital raising of approximately $20 million via a two-tranche institutional placement and a share purchase plan (SPP), issuing new shares at $0.18 to Australian and international investors and eligible shareholders.The comp...
Imugene posts high response rates for azer-cel in early CAR T-naïve lymphoma trial
Mar 9, 2026
Imugene reported strong early efficacy data from the CAR T-naïve cohort of its Phase 1b basket study of azer-cel, an off-the-shelf allogeneic CAR T cell therapy for advanced B-cell cancers. The company is seeing faster enrolment in this cohor...
Imugene Seeks Trading Halt Ahead of Capital Raising Announcement
Mar 9, 2026
Imugene has requested an immediate trading halt in its securities on the ASX as it prepares to announce a proposed capital raising. The halt, granted under ASX Listing Rule 17.1, will remain in place until the capital-raising announcement is relea...
Imugene to Showcase Lead CAR T Therapy at Major TD Cowen Health Care Conference
Feb 27, 2026
Imugene Limited, a clinical-stage immuno-oncology company, will present clinical data on its lead program azer-cel, an allogeneic off-the-shelf CAR T cell therapy, at the TD Cowen 46th Annual Health Care Conference in Boston. Chief Medical Officer...
Imugene secures A$2.7m R&D tax refund to advance cancer pipeline
Feb 25, 2026
Imugene Limited has received an A$2.74 million research and development tax refund from the Australian Government’s RD Tax Incentive program for the 2025 financial year. The non-dilutive funding, which includes interest, strengthens the comp...
Imugene Narrows Half-Year Loss but Net Tangible Assets Fall
Feb 25, 2026
Imugene reported a net loss attributable to members of $37.8 million for the half year ended 31 December 2025, representing a 22% reduction in losses compared with the prior corresponding period. The company recorded no revenue from ordinary activ...
Imugene Sets March 2026 Expiry for ASX-Listed Options
Feb 24, 2026
Imugene Limited has notified holders of its listed options on the ASX, trading under ticker IMUO, that these securities are exercisable at $0.43 each and will expire at 5:00 p.m. AEDT on 30 March 2026. Official quotation of the options will cease ...
Imugene Issues Small Tranche of Unquoted Options in Capital Structure Update
Feb 20, 2026
Imugene Limited has notified the market of the issue of 400 unquoted options expiring on 30 June 2028 with an exercise price of $0.86, issued on 16 February 2026. These options, documented via an Appendix 3G, form part of previously announced tran...
Imugene Issues 1.7 Million New Shares on Convertible Note Conversion
Jan 30, 2026
Imugene Limited has issued 1,736,111 fully paid ordinary shares to CVI Investment Inc. following the conversion of five zero coupon convertible notes, increasing its share capital without undertaking a separate disclosure to investors under the fu...
Imugene Posts Strong Azer-cel Data and Cuts Costs as It Advances Toward Pivotal Trial
Jan 30, 2026
Imugene reported strong Phase 1b clinical data for its allogeneic CD19 CAR T therapy azer-cel, achieving an 82% overall response rate in relapsed/refractory DLBCL, including seven complete and seven partial responses among 17 patients, with the fi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.